

[Drug Research](#)

•

[Pharmacopsychiatry](#)

•

[Synfacts](#)

•

[Synlett](#)

•

[Synthesis](#)

Related Books

•

[Chemistry](#)

Share / Bookmark

[CiteULike](#) [Delicious](#)

Planta Med 2014; 80 - P1L20

DOI: 10.1055/s-0034-1394678


Xanthenedione derivatives, new promising acetylcholinesterase inhibitor agents

A Seca ^{1,2}, S Leal ², D Pinto ², M do Carmo Barreto ^{1,3}, A Silva ²

- ¹DCTD, University of Azores, Rua Mãe de Deus, 9501 – 801 Ponta Delgada, Portugal
- ²Department of Chemistry & QOPNA, University of Aveiro, 3810 – 193 Aveiro, Portugal
- ³Centro de Investigação em Recursos Naturais, 9501 – 801 Ponta Delgada, Portugal
- [Congress Abstract](#)

Acetylcholinesterase inhibitors (AChEIs) are employed in medicine mostly for correcting the effects of insufficient levels of acetylcholine [1]. Xanthenes are a class of secondary metabolites associated with important pharmacological properties, being some of its derivatives AChEIs [2]. Xanthenedione derivatives are not widely spread in nature but their synthesis and bioactivities evaluation is still a hot topic. Following our interest in the synthesis of biologically active compounds, several xanthene-1,9(*2H*)-diones (*2a-2f*) were synthesized by simple and efficient methodologies from (*E,E*)-3-cinnamoyl-5-hydroxy-2-styrylchromones (Scheme 1) [3] and their acetylcholinesterase activity evaluated by a modification of the Ellman's method [4]. The results (Table 1) showed that variations in the substitution and hydroxylation pattern seem to be important for their activity, being the xanthenedione bearing a catechol unit the most potent AChEI, even more active than galantamine, an AChEI alkaloid used clinically in early stages of Alzheimer's disease. SAR studies showed that the presence of hydroxyl 3-aryl and 4-benzylidene moieties is essential for the activity. Furthermore xanthenedione *2c* showed a combination of partially competitive and non-competitive inhibition, while xanthenedione *2e* shows an almost pure competitive type inhibition. The most active xanthenediones *2e* and *2c* present zero violations of Lipinski's 'rule of five' and xanthenedione *2c* combine higher AChE activity with good oral bioavailability properties (TPSA < 140 Å²). The results suggest that they may be

excellent templates for drugs to be used in the prevention and treatment of neurodegenerative diseases.



Tab. 1: Acetylcholinesterase inhibitory effect of xanthenediones (2) and some intermediates (1).

| Compounds | Anti-AChE IC_{50} ($\mu M \pm SD$, $n = 4$) |
|--------------|---|
| 1a | > 381 |
| 1c | 122 ± 2.1 |
| 2a | > 381 |
| 2b | > 355 |
| 2c | 41.1 ± 6.1 |
| 2 d | > 325 |
| 2c | 31.0 ± 0.09 |
| 2f | > 325 |
| Galanthamine | 211.8 ± 9.5 |

Acknowledgements: Thanks are due to FCT, EU, QREN, FEDER and COMPETE, for funding the QOPNA research unit (project PEst-C/QUI/UI0062/2013; FCOMP-01 – 0124-FEDER-037296) and the Portuguese National NMR Network and also Azores University and FRC/Azores for funding CIRN.

Keywords: Xanthones, xanthene-1,9(2 H)-diones, acetylcholinesterase inhibitors, synthesis

References:

[1] Houghton, PJ, Ren, Y, Howes, MJ. Acetylcholinesterase inhibitors from plants and fungi. Nat. Prod. Rep. 2006; 23: 181 – 199.

[2] Brígida R. Pinho, BR, Ferreres, F, Valentão, P, Andrade, PB. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment. J. Pharm. Pharmacol. 2013; 65: 1681 – 1700.

[3] Pinto, DCGA, Seca, AML, Leal, SB, Silva, AMS, Cavaleiro, JAS. A novel short-step synthesis of new xanthenedione derivatives from the cyclization of 3-cinnamoyl-2-styrylchromones. Synlett 2011; 2005 – 2008.

[4] Barreto MC, Arruda M, Rego E, Medeiros JS, Rainha N. Cell-free assays. In: Barreto MC, Simões N. Determination of Biological Activities. A Laboratory Manual, N. Universidade dos Açores, Ponta Delgada; 2012: 65 – 81.

Top of Page

© 2014 Georg Thieme Verlag KG | [Impressum](#) | [Privacy](#) | [Smartphone Version](#)